| Year |
|---|
| Current Assets |
| Cash & Short Term Investments |
| Cash And Cash Equivalents |
| Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Non-Current Assets |
| Property, Plant & Equipment |
| Goodwill And Intangible Assets |
| Goodwill |
| Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Other Assets |
| Total Assets |
| Current Liabilities |
| Accounts Payable |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Total Non-Current Liabilities |
| Long-Term Debt |
| Deferred Revenue |
| Deferred Taxes Liabilities |
| Other Non Current liabilities |
| Total Liabilities |
| Other Liabilities |
| Stockholders Equity |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income/Loss |
| Other Shareholders Equity |
| Total Liabilities and Stockholders Equity |
Marksans Pharma Limited
MARKSANS.NS
NSE
205.58INR11.43 (6.52%)
MARKSANS.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 10.91B | 5.09B |
| Net Income | 3.14B | 2.66B |
| Stock Repurchases | 0 | -451.66M |
| Dividend Paid | -226.58M | -101.71M |
| Retained Earnings | 10.69B | 10.91B |
| Other Distributions | -450.69M | 5.27B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 6.93B | 3.87B |
| Annual Depreciation | 742.7M | 518.53M |
| Capital Expenditure | -2.09B | -536.31M |
| Net PPE | 8.28B | 3.89B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 10.1M | 84.64M |
| Goodwill (Previous Year) | 384.89M | 300.25M |
| Goodwill | 394.99M | 384.89M |